---
id: gene-editing
name: Gene Editing
family: technological
tier: active
url: https://futuremap.talin.digital/e/gene-editing/
license: CC-BY-NC-4.0
---

# Gene Editing

## Maturity
4/5 — Approved therapies in market; agricultural applications advancing; delivery, cost and governance are the binding constraints.

Source: Regulatory approval records for CRISPR-based therapies (2024–2026)

## What it is
Making targeted changes to a genome — CRISPR and its successors — in medicine, agriculture and industrial biology.

## What it does
It moves biology from reading to writing. The first approved therapies exist, which makes this one of the few frontier technologies in this Compendium with a delivered clinical outcome.

## Common misconception
That the constraint is technical. Delivery to the right cells, cost per patient, and the governance of heritable edits are each further from resolution than the editing itself.

## Steepens
- Longevity and the Healthspan Gap (longevity-and-the-healthspan-gap) — large
- Food System Transformation (food-system-transformation) — moderate
- Zoonotic and Antimicrobial Resistance Risk (zoonotic-and-antimicrobial-resistance-risk) — moderate
- Biodiversity Loss (biodiversity-loss) — marginal

## What would change its gradient
- In-vivo delivery, the central technical problem
- Cost per patient, which decides reach
- International governance of heritable editing, currently national and uneven
